The role of high-dose methylprednisolone therapy in paroxysmal nocturnal hemoglobinuria


Erduran E. , ASLAN Y. , GEDIK Y. , MOCAN H., OKTEN A. N.

TURKISH JOURNAL OF PEDIATRICS, vol.37, no.3, pp.283-287, 1995 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 1995
  • Title of Journal : TURKISH JOURNAL OF PEDIATRICS
  • Page Numbers: pp.283-287

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder characterized by intermittent hemolytic anemia. High-dose methylprednisolone (HDMP) was administered in two patients, eight- and 16-year-old females, with PNH. This drug produced a dramatic improvement in the hemoglobin level, leukocyte and platelet counts. No side effect was observed in either patient during the treatment period. The patients were followed up on an outpatient basis for six and 16 months. In conclusion, HDMP therapy for PNH appears to be more effective and safe than previously reported therapies.